中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

48 records (took 0.021 seconds)

    31.
    发明专利
    未知

    公开(公告)号：AT114320T

    公开(公告)日：1994-12-15

    申请号：AT90115455

    申请日：1990-08-11

    Applicant: HOECHST AG

    Inventor： HENKE STEPHAN DR ,  BREIPOHL GERHARD DR ,  KNOLLE JOCHEN DR ,  SCHOELKENS BERNWARD PROF DR ,  GERHARDS HERMANN DR

    IPC: A61K38/00 ,  A61K38/08 ,  A61P43/00 ,  C07K1/06 ,  C07K7/06 ,  C07K7/08 ,  C07K7/18 ,  A61K37/02

    Abstract: Peptides of the formula I A-B-C-E-F-K-(D)-Phe-G-M-F'-I (1> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, aryloyl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aromatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F or can be -NH-(CH2)2-8 or optionally a direct bond, I is -OH, -NH2 or -NHC2H5, and K is a radical -NH-(CH2)1-4-CO- or is a direct bond, act as bradykinin antagonists. Their therapeutic uses comprise all pathological states promoted, induced or assisted by bradykinin and bradykinin-related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.

    New fused imidazole derivs are angiotensin II antagonists
    35.
    发明专利
    New fused imidazole derivs are angiotensin II antagonists 未知

    公开(公告)号：DE4131325A1

    公开(公告)日：1993-04-01

    申请号：DE4131325

    申请日：1991-09-20

    Applicant: HOECHST AG

    Inventor： HEITSCH HOLGER DR ,  WAGNER ADALBERT DR ,  KLEEMANN HEINZ-WERNER DR ,  GERHARDS HERMANN DR ,  SCHOELKENS BERNWARD PROF DR

    IPC: C07D235/08 ,  C07D409/06 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00

    Abstract: Fused imidazole derivs. of formula (I) and their physiologically acceptable salts are new. In (I) X = a monocyclic gp. with 3, 4 or 5 ring atoms or a bicyclic gp. with 8-10 ring atoms, which is completely or partially hydrogenated and in which one or more CH or CH2 gps. are replaced with N, NH or O; R1 = 1-10C alkyl, 3-10C alkenyl, 3-10C alkynyl, (these 3 gps. being opt. mono-substd. with CO2R6 and opt. having 1 to all of their H atoms replaced with F), etc.. R2, R3, R4 and R5 = each H, halogen, OH, CN, NO2, sulpho, formyl, benzoyl, 1-8C acyl, 1-8C acyloxy, SH, etc.. R6 = H, 1-8C alkyl (in which 1 to all H atoms are opt. replaced with F) 3-8C cycloalkyl, Ph, benzyl; L = 1-3C alkane diyl; R12 and R13 = each H, halogen, NO2, 1-4C alkyl or 1-2C alkoxy; q = 0-1; A = either a heterocycle with 5-10 ring atoms, which is mono or bicyclic and in which up to 9 ring atoms are C and which is opt. substd. with up to 6 (esp. up to 3) opt. different gps. R14 and R15; or A is opt. substd. biphenyl.

    (Aminoalkyl- and acylaminoalkyl-oxy)benzyloxyquinolines, process for their preparation and use as Bradykinin receptor antagonists
    38.
    发明专利
    (Aminoalkyl- and acylaminoalkyl-oxy)benzyloxyquinolines, process for their preparation and use as Bradykinin receptor antagonists 未知

    公开(公告)号：GR3033415T3

    公开(公告)日：2000-09-29

    申请号：GR20000401105

    申请日：2000-05-16

    Applicant: HOECHST AG

    Inventor： HEITSCH HOLGER DR ,  WAGNER ADALBERT DR ,  WIRTH KLAUS DR ,  SCHOELKENS BERNWARD PROF DR ,  NOELKEN GERHARD DR

    IPC: C07D215/48 ,  A61K31/47 ,  A61P43/00 ,  C07D215/26

    Abstract: 8-(3-(Aminoalkoxy)-benzyloxy)-quinoline compounds of formula (I) and their salts are new. R1-R3 = H, halo, CHO, COOH, 1-5C alkyl, 6-10C aryl, 1-3C alkyl-(6-10C) aryl, 3-8C cycloalkyl or 1-3C alkoxycarbonyl; R4, R5 = H, halo, NO2, CN, 1-3C alkoxy or 1-3C alkylthio; R6 = H, 1-3C alkyl, 3-5C alkylalkenyl (sic) or 1-3C alkyl-6-10C aryl; R7 = H, 1-6C alkanoyl, alkanoyl (substituted by 1-3C alkoxy, alkylcarbamoyl or aryl), 3-7C alkenoyl, 3-8C cycloalkylcarbonyl, 5-7C cycloalkenylcarbonyl, 1-3C alkoxycarbonyl, aryloxycarbonyl, 6-12C aroyl (optionally substituted by 1-3C alkoxy or halo), alkenoyl (substituted by aryl (optionally substituted by 1-3C alkoxy, 1-3C alkylenedioxy, NO2, CN, halo, 1-3C haloalkyl, hetero-3-8C cycloalkyl (sic), NH2, 1-4C alkylamino, 6-12C heteroaryl-alkanoylamino, aroylamino, 6-12C heteroarylcarbonylamino, 1-5C alkylsulphonylamino, 1-5C alkylureido, alkanoyl, 1-5C alkoxycarbonyl, 1-5C alkylcarbamoyl or arylcarbamoyl), 2-5C acylamino-arylcinnamoyl, 1-3C alkoxycarbonylamino-arylcinnamoyl, 1-4C alkylaminocarbonylaminocinnamoyl, aryl-1-5C alkoxycarbonyl, 1-5C alkylcarbamoyl, arylcarbamoyl, aroylcarbamoyl, alkylsulphonyl, arylsulphonyl, aryl-alkylsulphonyl or phthaloyl (for R6=R7(sic)); n = 1-8; alkyl has 1-6C, aryl has 6-12C, alkanoyl has 2-6C, and alkenoyl has 3-6C unless specified other wise.

Patent Agency Ranking